NDAORALTABLET
Approved
Jan 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
21
Data completeness
4/8 — Partial
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NESINA (alogliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved in 2013 for type 2 diabetes mellitus. It works by increasing incretin hormone levels to improve glycemic control in patients with inadequate diabetes management. The drug is administered orally as a tablet and represents a small-molecule approach to diabetes management.
$0.4MPart D
LOE ApproachingDeclining
3.0 years to LOEWith only $400K in Part D spending and 916 claims in 2023, this product is losing market share as patent expiration approaches; commercial teams are likely in maintenance mode with minimal expansion headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Started Jul 2025
171 enrolled
T2DMDiabete Type 2DM
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
Started Jun 2019
1,293 enrolled
Type 2 Diabetes Mellitus
A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants
Started May 2018
72 enrolled
Healthy Volunteers
Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
Started Jul 2017
0Diabetes Mellitus, Type 2
Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function
Started Jul 2017
96 enrolled
Diabetes
Worked on NESINA at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.